Odylia Therapeutics Inc is a nonprofit organization dedicated to accelerating the development of gene therapies for individuals with rare diseases, particularly focusing on eye diseases, blindness, and vision impairments, as well as addiction services. With an operating budget of $699.4K and total revenue of $482K for the filing year 2024, the organization is supported by multiple significant funders, none of which contribute 50% or more of its revenue. For more information, visit their website at www.odylia.org.